Total Synthesis of Lignan Lactone (–)-Hinokinin by unknown
ORIGINAL ARTICLE
Total Synthesis of Lignan Lactone (–)-Hinokinin
Qi-Long Zhou . Hui-Jing Wang . Pei Tang .
Hao Song . Yong Qin
Received: 3 September 2015 / Accepted: 22 September 2015 / Published online: 12 October 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract This research paper is aimed at studying the total synthesis of pharmacologically active lignan (–)-hinokinin.
The synthesis features a three-step cascade reaction involving highly stereoselective Michael addition, anion-oxidative
hydroxylation, and oxygen anion cyclization to construct the pivotal butyrolactonimidate intermediate.
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1 Introduction
Lignans are a large class of natural products that were
isolated from many plants [1, 2] (Fig. 1). They display
diverse biological activities, especially antiviral and anti-
tumor properties. For example, hinokinin (1) [3–5] has
been found to exhibit antileukemic, antiviral, antifungal,
and pesticidal activities [6–26]. Mammalian lignin
enterolactone (2), which is formed by the action of
intestinal bacteria from plant lignan precursors present in
the diet, inhibit breast cancer and colon cancer, and may
also inhibit cardiovascular disease [27, 28]. Furthermore,
podophyllotoxin (3), steganacin (4) and tetrahydrofuran
lignan burseran (5) show strong cytotoxic activity against
various cancer cell lines by preventing the normal function
of the mitotic spindle [29–36]. In addition, the furofuran
lignan methyl piperitol (6) possesses platelet activating
factor (PAF) antagonist activity [37]. Due to their inter-
esting biological activities, several members of this family
of natural products and their analogs have therefore been
the target of extensive synthetic research [38–47].
We recently developed a one-pot, three-step cascade
reaction from enantiomerically pure (R)-N-tert-butane-
sulfinyl imidates 7 and a,b-unsaturated diesters 8 [48] to
generate butyrolactonimidates 11 (Scheme 1). This reac-
tion proceeded through highly stereoselective Michael
addition (7–9), followed by anion-oxidative hydroxylation
(9–10) and oxygen anion cyclization (10–11). The syn-
thesized butyrolactonimidates 11 are versatile intermedi-
ates for preparing substituted butyrolactones and furans.
We also used this approach to achieve the concise total
synthesis of natural product (–)-nephrosteranic acid [48]. In
this paper, we report the total synthesis of lignan lactone
(–)-hinokinin 1 as shown in Schemes 2 and 3.
2 Results and Discussion
We began our synthesis with the preparation of enantiopure
(R)-N-tert-butanesulfinyl imidate 14 (Scheme 2): treatment
of the known nitrile 12 [49, 50] with gaseous HCl in
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methanol yielded a good amount of trimethylorthoester
intermediate [51], subsequent condensation of (R)-tert-
butanesulfinamide 13 and the corresponding trimethy-
lorthoester with a catalytic amount of p-TsOH without
solvent afforded chiral (R)-N-tert-butanesulfinyl imidate 14
in 76 % overall yield [52–54]. With the N-sulfinyl imidate
14 in hand, we focused our attention on the construction of
the pivotal butyrolactonimidate, as shown in Scheme 2.
Firstly, we performed the one pot protocol between 14 and
the known a,b-unsaturated diester 15 [55, 56] under opti-
mal condition [48] {LiHMDS (5.0 equiv), -78 C;
Cu(OTf)2 (5.0 equiv), -78 to 60 C} to afford the desired
butyrolactonimidate 16 in low yield (20 %), due to the
isomerization of double bond in 15 under excess LiHMDS.
To our delight, the stepwise procedure provided a satis-
factory result. Indeed, a LiHMDS-mediated highly stere-
oselective Michael addition of 14–15 produced adduct 17
in 80 % yield as the dominant stereoisomer (dr 55:2:1:0 by
LC–MS). Next, the resulting Michael adduct underwent the
Cu(OTf)2-mediated anion-oxidative hydroxylation and
oxygen anion cyclization to deliver 16 in 83 % yield.
With the pivotal butyrolactonimidate 16 in hand, the
synthesis of natural product (–)-hinokinin 1 was investi-
gated (Scheme 3). The chiral tert-butylsulfinyl moiety in
16 was readily removed by TFA in CH2Cl2 to afford
butyrolactone 18 in 80 % yield. Krapcho demethoxycar-
bonylation of 18 with LiCl in DMSO afforded 19 in 90 %
yield as a 5:1 mixture of epimers [57–59], as determined by
1H NMR spectroscopy. The mixture of epimers could not
be separated by chromatography, however this would
prove to be inconsequential since this carbon would
become sp2 hybridized in subsequent steps. Reduction of
the ester group in mixture 19 with NaBH4 in MeOH gave
alcohol 20 in 78 % yield. Subsequent reduction of the
lactone group in 20 using InBr3 and Et3SiH in CHCl3
generated the desired furan 21 in 60 % yield as a mixture
Scheme 1 Synthesis of
butyrolactonimidates 11 via the
three-step cascade reaction
Fig. 1 Representive lignans
with pharmacological activities
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of epimers [60, 61]. Interestingly, besides furan 21, further
aromatic oxidative coupling proceeded under this condition
to deliver compound 22 in 20 % yield, which possessed the
tetracyclic scaffold of dibenzocyclooctadiene lignans such
as steganacin 4 (Fig. 1). The generation of 22 presumably
resulted from the introduction of oxygen under this
reductive condition, and the amount of 22 was considerably
increased (TLC monitoring) when oxygen was intention-
ally bubbled into the reaction tube. Finally, heating of 21
with excess PCC in toluene completed the total synthesis of
lignan lactone (–)-hinokinin 1 in acceptable yield [62, 63],
which displayed identical spectral properties to the repor-
ted data [3–5, 18, 21, 24, 26].
3 Conclusion
In summary, we accomplished the total synthesis of the
lignan lactone (–)-hinokinin 1 in 8 steps. The synthesis is
based on a three-step cascade reaction involving highly
Scheme 2 Synthesis of butyrolactonimidate 16. Reagents and con-
ditions: a HCl (gas), MeOH, 0 C, 24 h; MeOH, r.t., 48 h; then (R)-
tert-butanesulfinamide 13, p-TsOH (0.05 equiv), neat, 60 C, 24 h,
76 % in 2 steps; b LiHMDS (5.0 equiv), THF, -78 C, 0.5 h, then
Cu(OTf)2 (5.0 equiv), -78 to 60 C, 24 h, 20 %. c LiHMDS (2.2
equiv), THF, -78 C, 12 h, 80 %; d LiHMDS (3.3 equiv), THF,
-78 C, 0.5 h, then Cu(OTf)2 (5.0 equiv), -78 to 60 C, 24 h, 83 %.
LiHMDS Lithium hexamethyldisilazide, THF tetrahydrofuran
Scheme 3 Synthesis of (–)-hinokinin (1). Reagents and conditions:
a TFA (10.0 equiv), CH2Cl2, 0 C to r.t., 80 %; b LiCl (5.0 equiv),
DMSO, 100 C, 8 h, 90 %; c NaBH4 (2.5 equiv), MeOH, 0 C, 10 h,
78 %; d InBr3 (0.05 equiv), Et3SiH (5 equiv), CHCl3, sealed tube,
60 C, 2 h, 60 % for 21, 20 % for 22; e PCC (5.0 equiv), PhMe,
80 C, 5 h, 53 %. LiHMDS Lithium hexamethyldisilazide, THF
tetrahydrofuran, TFA trifluoroacetic acid, DMSO dimethyl sulfoxide,
PCC pyridinium chlorochromate
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stereoselective Michael addition, anion-oxidative hydrox-
ylation, and oxygen anion cyclization to construct the
pivotal butyrolactonimidate 16. The strategy we developed
may find use in the synthesis of other pharmacologically
active lignans.
4 Experiment Section
All commercially available reagents were used without
further purification. All solvents were dried and distilled
before use; THF was distilled from sodium. Chromatog-
raphy was conducted by using 200–300 mesh silica gel.
Petroleum ether refers to the 60–90 C boiling fraction. All
new compounds gave satisfactory spectroscopic analyses
(IR, 1H NMR, 13C NMR, HRMS). IR spectra were recor-
ded on a FT IR spectrometer. NMR spectra were recorded
on 600/400 MHz NMR spectrometers. HRMS spectra were
obtained by the ESI-TOF method. Experimental conditions
and spectral data were published previously for compounds
12 [49, 50] and 15 [55, 56].
4.1 Methyl (R,Z)-3-(benzo[d][1,3]dioxol-5-yl)-N-(tert-
butylsulfinyl)propanimidate (14)
(1) A mixture of the chosen nitrile 12 (28.60 mmol, 1.0
equiv) and methanol (37.00 mmol, 1.3 equiv) was
charged in a 50 mL flask, and cooled in an ice bath.
Gaseous HCl was slowly bubbled into the methanolic
solution of the nitrile for 20 min. The resulting mix-
ture was kept at 0 C for 24 h. Then, the excess of
methanol and HCl was removed by washing with
Et2O, white solid imidate hydrochloride was sepa-
rated. The product was dried under vacuum at rt, and
used as such for the subsequent methanolysis step.
(2) At rt, a mixture of methanol (10 mL) and the solid
imidate hydrochloride was set to react under stirring
for 48 h. A clear solution was obtained. White solid
(ammonium chloride) was formed during the reac-
tion. Then, the mixture was filtered to cleavage
NH4Cl and washed with Et2O. The solvent was
removed in vacuo to get the colorless oil trimethyl-
intermediate (6.5 g, 90 %).
(3) Under N2, to neat trimethyl-intermediate (9.84 mmol,
2 equiv) was added (R)-tert-butanesulfinamide 13
(4.92 mmol, 1 equiv) and p-TsOH (0.25 mmol, 0.05
equiv). The reaction mixture was kept at 60 C for
24 h. The resulting residue was purified by column
chromatography (silica gel) to give 14 (1.3 g, 84 %) as
a colorless oil. a½ 23D -97.0 (c 0.22, CH2Cl2); 1H NMR
(400 MHz, CDCl3) d 6.64–6.72 (m, 3H), 5.09 (s, 2H),
3.51 (s, 3H), 2.86–2.93 (m, 4H), 1.18 (s, 9H); 13C NMR
(100 MHz, CDCl3) d 175.6, 147.6, 146.0, 133.8, 121.2,
108.8, 108.2, 100.8, 55.8, 54.1, 34.8, 32.1, 21.8; HRMS
[M ? Na]? calcd for C15H21NNaO4S 334.1083, found
334.1084; IR (KBr) 2948, 1608, 1491, 1443, 1245,





Under N2, to a solution of 14 (1.90 mmol, 0.95 equiv) in
dry THF (100 mL) was added LiHMDS (1 M in THF,
4.20 mmol, 2.2 equiv) at -78 C. After the resulting
solution was maintained at -78 C for 30 min, a solution
of 15 (2.00 mmol, 1.0 equiv) in THF (1 mL) was slowly
added for 10 h. The resulting solution was maintained at
-78 C for another 12 h. The dr values for the first
Michael addition anaylsed by LC–Ms. After the reaction
was completed, the solution was quenched at -78 C by
pouring into aqueous NH4Cl (50 mL). The aqueous layer
was partitioned with EtOAc (3 9 50 mL). The organic
layer was separated, dried (Na2SO4), filtered, and the sol-
vent was removed in vacuo. Flash chromatography (silica
gel) of the crude reaction mixture afforded pure coupled
product 17 (900 mg, 80 %). Conditions for LC–MS anal-
ysis of Michael addition product: Waters ACOUITY UPLC
BEH C18, BEH C18 (2.1 9 100 mm, 1.7 micron particle
size), mobile phase H2O/CH3CN (80:20); Flow = 0.2 mL/
min; Detected by UV at 210 nm; Retention time for
stereoisomers: 7.78 min (major), 8.25 min, 8.97 min; Dr
55:1:2:0. 17: a½ 23D -44.2 (c 0.21, CH2Cl2); 1H NMR
(400 MHz, CDCl3) d 6.62–6.76 (m, 4H), 6.47–6.49 (m,
2H), 5.91 (s, 2H), 5.86 (s, 2H), 3.81–3.84 (m, 1H), 3.73 (s,
3H), 3.68(s, 3H), 3.67 (s, 3H), 3.59 (d, J = 4.0 Hz, 1H),
2.79–3.01 (m, 1H), 2.66–2.69 (m, 4H), 0.96 (s, 9H); 13C
NMR (100 MHz, CDCl3) d 175.2, 169.4, 168.6, 147.5,
146.2, 145.8, 134.0, 132.2, 122.2, 122.0, 109.5, 109.3,
108.2, 108.0, 100.8, 55.6, 53.8, 53.5, 52.5, 52.4, 47.8, 42.6,
36.7, 35.4, 21.6; HRMS [M ? Na]? calcd for
C29H35NNaO10S 612.1874, found 612.1876; IR (KBr)





Under N2, to a solution of 17 (1.82 mmol, 1 equiv) in dry
THF (200 mL) was added LiHMDS (1 M in THF,
6.00 mmol, 3.3 equiv) at -78 C. After the resulting
solution was maintained at -78 C for 30 min, the
258 Q.-L. Zhou et al.
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Cu(OTf)2 (9.10 mmol, 5.0 equiv) was added at once (ex-
posed to air for seconds). Then the reaction mixture was
warmed to ambient temperature slowly and kept at 60 C
and charged with nitrogen balloon for 24 h. After the
reaction was completed, the solution was kept in room
temperature and quenched by pouring it into aqueous
NH4Cl (100 mL). The aqueous layer was partitioned with
EtOAc (3 9 100 mL). The organic layer was separated
and washed with with HCl (1 N, 50 mL), water (50 mL)
and aqueous NaHCO3 (50 mL), dried (Na2SO4), filtered,
and the solvent was removed in vacuo. Flash chromatog-
raphy (silica gel) of the crude reaction mixture afforded
pure coupled product 16 (860 mg, 83 %). a½ 23D -77.0
(c 0.15, CH2Cl2);
1H NMR (400 MHz, CDCl3) d 6.41–6.62
(m, 6H), 5.88–5.94 (m, 4H), 3.89 (s, 3H), 3.84 (s, 3H),
2.61–2.91 (m, 5H), 2.13–2.17 (m, 1H), 1.10 (s, 9H); 13C
NMR (150 MHz, CDCl3) d 171.1, 166.1, 147.4, 146.1,
130.7, 122.4, 122.1, 109.6, 109.1, 108.2, 107.8, 101.1,
100.8, 60.4, 53.9, 53.4, 53.3, 45.8, 30.9, 22.2, 21.03, 14.2;
HRMS [M ? Na]? calcd for C28H31NNaO10S 596.1561,
found 596.1569; IR (KBr) 2962, 2926, 1749, 1665, 1504,




To a solution of 16 (0.80 mmol, 1.0 equiv) in DCM (30 mL)
cooled in an ice-water bath was added TFA (8.00 mmol, 10.0
equiv), and the mixture was stirred at room temperature for
24 h. The reaction was quenched by the addition of sat.
NaHCO3. The mixture was extracted with EtOAc
(30 mL 9 3), dried over Na2SO4 and then concentrated. The
resulting residue was purified by column chromatography
(silica gel) to give 18 (240 mg, 80 %) as a white solide. a½ 23D
?8.0 (c 0.12, CH2Cl2);
1H NMR (400 MHz, CDCl3) d 6.72
(d, J = 8.4 Hz, 1H), 6.59–6.67 (m, 3H), 6.20–6.22 (m, 2H),
5.97(d, J = 4.8 Hz, 2H), 5.91 (d, J = 4.6 Hz, 2H), 3.86 (s,
3H), 3.84 (s, 3H), 3.03–3.10 (m, 2H), 2.73-2.85 (m, 2H),
2.44–2.48 (m, 1H), 2.23 (m, 1H); 13C NMR (150 MHz,
CDCl3) d 175.6, 166.8, 166.7, 148.0, 147.5, 146.6, 146.3,
130.9, 130.0, 122.6, 122.1, 109.8, 109.4, 108.3, 108.0, 101.1,
100.9, 85.7, 53.6, 53.4, 46.5, 45.0, 36.6, 34.5; HRMS
[M ? Na]? calcd for C24H22NaO10 493.1105, found
493.1107; IR (KBr) 2956, 2924, 1796, 1748, 1492, 1445,
1250, 1175, 1081, 1039, 930, 862, 810, 737, 651.
4.5 (3R,4R)-methyl 3,4-bis(benzo[d][1,3]dioxol-5-
ylmethyl)-5-oxotetrahydrofuran-2-carboxylate (19)
To a solution of 18 (0.45 mmol, 1.0 equiv) in DMSO
(9 mL) was added LiCl (2.25 mmol, 5.0 equiv), and the
mixture was stirred at 100 C for 8 h. The reaction was
quenched by the addition of water (10 mL). The mixture
was extracted with EtOAc (10 mL 9 3), dried over
Na2SO4 and then concentrated. The resulting residue was
purified by column chromatography (silica gel) to give
yellow oil 19 (167 mg, 90 %) as a mixture (dr 5:1). 1H
NMR (400 MHz, CDCl3) d 6.66 (d, J = 7.8 Hz, 2.4H),
6.34–6.52 (m, 4.8H), 5.92 (d, J = 6.5 Hz, 4.8H), 4.75 (d,
J = 7.9 Hz, 0.2H) (minor), 4.53 (d, J = 4.6 Hz, 1H)
(major), 3.78 (s, 0.6H), 3.74 (d, J = 1.8 Hz, 3H),
2.92–2.97 (m, 1.2H), 2.63–2.78 (m, 2.4H), 2.58 (m, 3.6H).
13C NMR (100 MHz, CDCl3) d 177.2, 176.7, 170.0, 169.1,
147.8, 146.5, 131.0, 130.8, 130.4, 130.0, 122.3, 122.1,
121.7, 109.6, 109.4, 109.3, 108.9, 108.3, 108.2, 101.1,
78.5, 77.4, 52.7, 52.4, 45.7, 44.9, 44.5, 43.1, 38.4, 35.7,




To a solution of 19 (0.47 mmol, 1.0 eq) in MeOH (17 mL)
cooled in an ice-water bath was added NaBH4 (2.50 mmol,
2.5 eq), and the mixture was stirred in an ice-water bath for
10 h. The reaction was quenched by the addition of sat.
NH4Cl (5 mL). The mixture was extracted with EtOAc
(10 mL 9 5), dried over Na2SO4 and then concentrated.
The resulting residue was purified by column chromatog-
raphy (silica gel) to give 20 (140 mg, 78 %) as a yellow
oil. 1H NMR (400 MHz, CDCl3) d 6.70 (m, 2.4H),
6.55–6.66 (m, 2.4H), 6.46 (d, J = 8.2 Hz, 2.4H), 5.84–5.98
(s, 4.8H), 4.25–4.30 (m, 0.2H), 4.17–4.23 (m, 1H), 3.52 (d,
J = 12.6 Hz, 1.2H), 3.13 (dd, J = 12.9, 4.8 Hz, 1.2H),
2.64–2.84 (m, 2.4H), 2.36–2.50 (m, 4.8H); 13C NMR
(100 MHz, CDCl3) d 177.4, 147.8, 146.4, 132.1, 131.3,
122.3, 121.7, 121.4, 109.5, 108.7, 108.4, 108.3, 108.3,
108.1, 101.0, 83.7, 80.4, 63.1, 61.9, 47.5, 46.6, 42.0, 41.6,
38.7, 35.3, 34.8, 34.1. HRMS [M ? Na]? calcd for







To a freshly distilled CHCl3 solution (10 mL) was added
successively 20 (0.65 mmol, 1.0 equiv), a catalytic amount
of InBr3 (0.03 mmol, 0.05 equiv), and Et3SiH (3.25 mmol,
5.0 eq). The solution was maintained at 60 C for 2 h.
During the stirring of the reaction mixture at 60 C (bath
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temperature), the solution turned from colorless to yellow,
then to white. The reaction was monitored by TLC until the
consumption of the starting lactone. After the reaction,
H2O (3 mL) was added, and the resulting orange suspen-
sion was stirred continuously until the disappearance of the
color. The aqueous layer was partitioned with EtOAc
(3 9 10 mL). The organic layer was separated, dried
(Na2SO4), filtered, and the solvent was removed in vacuo.
Flash chromatography (silica gel) of the crude reaction
mixture afforded product 21 (143 mg, 60 %) and 22
(48 mg, 20 %) as a colorless oil. 21: 1H NMR (400 MHz,
CDCl3) d 6.68 (m, 2.4H), 6.54 (m, 4.8H), 5.91 (s, 4.8H),
3.90–4.10 (m, 0.2H), 3.82 (td, J = 8.0, 7.0, 2.0 Hz, 1H),
3.64–3.71 (m, 1.2H), 3.54–3.59 (m, 1.2H), 3.43 (dd,
J = 11.8, 2.7 Hz, 1.2H), 3.23–3.37 (m, 1.2H), 2.41–2.65
(m, 4.8H), 2.13–2.25 (m, 1.2H), 1.86–1.92 (m, 1.2H); 13C
NMR (100 MHz, CDCl3) d 147.7, 147.6, 146.0, 145.8,
133.9, 133.4, 121.6, 121.4, 109.0, 108.9, 108.2, 108.1,
100.9, 85.6, 72.4, 64.0, 47.4, 47.1, 39.0. HRMS
[M ? Na]? calcd for C21H22NaO6 393.1314, found
393.1317. 22: 1H NMR (400 MHz, CDCl3) d 6.96 (s,
1.2H), 6.85 (s, 1.2H), 6.62 (s, 1.2H), 6.48 (s, 1.2H),
5.70–6.03 (m, 4.8H), 4.15 (d, J = 7.9 Hz, 1.2H), 3.89 (dd,
J = 10.4, 2.3 Hz, 1.2H), 3.53–3.78 (m, 2.4H), 3.19-3.41
(m, 1.2H), 2.55-2.98 (m, 4.8H), 2.45–2.50 (m, 1.2H),
2.08–2.16 (m, 1.2H); 13C NMR (100 MHz, CDCl3) d
146.8, 146.3, 146.3, 145.7, 139.2, 135.3, 130.8, 127.5,
108.6, 108.0, 105.6, 105.4, 100.9, 100.7, 77.2, 73.9, 65.2,
47.8, 39.9, 38.3, 30.8, 28.2. HRMS [M ? Na]? calcd for
C21H20NaO6 391.1152, found 391.1143.
4.8 (3R,4R)-3,4-bis(benzo[d][1,3]dioxol-5-
ylmethyl)dihydrofuran-2(3H)-one (1)
To a solution of 21 (0.08 mmol, 1.0 eq) dry toluene (3 mL)
was added PCC (0.40 mmol, 5.0 eq) and 4A˚ MS (30 mg),
the mixture was stirred at 80 C for 5 h. After the reaction,
the mixture was filtered through a pad of Celite, and
washed with EtOAc for 5 times and then concentrated. The
resulting residue was purified by column chromatography
(silica gel) to give (–)-hinokinin 1 (15 mg, 53 %) as a
white solide. a½ 23D -31 (c 0.21, CHCl3), {lit. [5] a½ 21D -34
(c 2.85, CHCl3); lit. [21] a½ 26D -30 (c 0.99, CHCl3)}; 1H
NMR (400 MHz, CDCl3) d 6.44–6.73 (m, 6H), 5.92 (s,
4H), 4.11 (dd, J = 9.0, 6.7 Hz, 1H), 3.85 (dd, J = 9.2,
6.8 Hz, 1H), 2.97 (dd, J = 14.1, 5.0 Hz, 1H), 2.83 (dd,
J = 14.1, 7.3 Hz, 1H), 2.48–2.65 (m, 2H), 2.45 (m, 2H).
13C NMR (100 MHz, CDCl3) d 178.4, 147.8, 146.4, 146.3,
131.5, 131.2, 122.2, 121.5, 109.4, 108.8, 108.3, 108.2,
100.9, 71.1, 46.4, 41.2, 38.3, 34.8. The NMR data match
those reported in the literature [3–5, 18, 21, 24, 26]. HRMS
[M ? Na]? calcd for C20H18NaO6 377.1001, found
377.1004; IR (KBr), 2958, 2924, 2855, 1761, 1503, 1489,
1443, 1257, 1189, 1098, 1036, 925, 864, 807, 771, 734,
676, 515.
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